UK regulators have approved the resumption of a global trial aimed at determining whether hydroxychloroquine and chloroquine are effective in preventing COVID-19 infections in healthcare settings, according to Reuters.
The trial, known as COPCOV, was paused after another British study found the drugs to be ineffective in treating the virus, however the Medicines and Healthcare Products Regulatory Agency (MHRA) has now allowed the research to resume following positive COPCOV trial results.
“Participants will take the study drugs each day for a period of three months, and will be followed closely to see how well the drug is tolerated, whether they contract the virus, and if they do, whether they develop mild or more severe COVID-19,” according to Tropical Health Network.
According to Reuters, COPCOV is a “randomised, placebo-controlled trial that is aiming to enrol 40,000 healthcare workers and other at-risk staff around the world,” conducted by Oxford University’s Bangkok-based Mahidol Oxford Tropical Medicine Research Unit (MORU).
The study is funded in part by the Bill & Melinda Gates Foundation. Unsurprisingly, their website makes no mention of the inclusion of zinc – largely credited by pro-HCQ physicians as the key ingredient to the treatment. – READ MORE
Listen to the insightful Thomas Paine Podcast Below --